Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Patient Education on Kidney Recipients Knowledge, Coping and Quality of Life. A Randomized Controlled Trial.
Brief Summary: For patients with end-stage kidney disease, transplantation is the treatment of choice, offering improved quality of life by restored metabolism and freedom from dialysis. However, demands regarding the acquirement of knowledge in life post transplantation are high. In order to reduce rejection episodes, graft loss and the negative consequences of life-long immunosuppressive medication, it is essential for kidney recipients to possess knowledge about important aspects regarding immunosuppressive medication, graft surveillance and the benefit of specific lifestyle behavior. Consequently, patient education is required for this patient group. This randomized controlled trial is investigating the effect of a structured patient education program on kidney recipients' knowledge, coping and quality of life


Options:
A: Inclusion Criteria:

* Recipients of first kidney transplants (deceased or living donor) with stable allograft function
* 6 or more months after transplantation
* Currently on a stable dose of twice-daily tacrolimus and mycophenolate mofetil (MMF) or enteric coated mycophenolic acid (EC-MPA)± corticosteroids for a minimum of 6 months prior (patient has remained on a dosing that has changed no greater than ± 0.5mg/dose for a minimum of 4 months)
* Ability to comply with study procedures for the entire length of the study
* Patient and/or parent/legal guardian has been informed about the study survey and has signed an informed consent form.

Exclusion Criteria:

* Detectable donor specific anti-HLA antibody prior to enrollment (pre- or post-transplant)
* Actively being treated for an episode of biopsy proven acute cellular rejection (ACR) (Banff 1A or greater)
* Post-transplant history of biopsy proven ACR (Banff 1B or greater) or antibody mediated rejection (AMR)
* Currently receiving, planning to receive, or received within 7 days prior to study enrollment any drug interacting or interfering with tacrolimus metabolism (azole antifungals, erythromycin, clarithromycin, diltiazem, protease inhibitors, statins, grapefruit juice, rifampin or anti-seizure medications shown to interact with tacrolimus)
* Currently receiving an mTOR inhibitor (sirolimus, everolimus)
* Gastrointestinal illness that might affect the absorption of tacrolimus
* Unable or unwilling to complete study survey questionnaire
* Professional care taker is responsible for dispensing subject's medication
* Recipient of HLA identical or zero HLA mismatched organ transplant
* Documented history of medication non-adherence following transplantation prior to enrollment
B: Inclusion Criteria:

* being over 18
* recently had a kidney transplant
* able to speak, understand and read Norwegian
* mentally able to participate in the study
C: Inclusion Criteria:

* all eligible patients with follow-up at our outpatient clinic
* written informed consent
* sufficient German language skills to read and answer a battery of questionnaires
* \> 18 years
* minimum 6 mts post HTX

Exclusion Criteria:

* illiteracy
D: Inclusion Criteria:

* Patients at least 6 months after lung transplantation (single, double or combined)
* Informed consent
* At least 10 trough levels analyzed in MHH reference lab in last 6 months
* \< 50% of calcineurin inhibitor trough levels in target range in last 6 months in outpatient clinic

Exclusion Criteria:

* Hospitalization during last 3 months
* BOS stage 3 (FEV1 \< 50% baseline)
* End stage kidney disease (GFR \<15 ml/min/1.73 m2 or renal replacement therapy)
* Oxygen requirement at rest
* Steroid pulse therapy (\>500 mg methylprednisolone per day) during the last 4 weeks
* Illiteracy
* Need for isolation (Colonization with multi. or pan resistant organisms, e.g. MRSA, B. cenocepacia)
* limited German language skills or other reasons which might impair patient communication or computer handling

Answer: B